134 related articles for article (PubMed ID: 8349861)
21. Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis.
Neal RA; Murphy AG; Olliaro P; Croft SL
Trans R Soc Trop Med Hyg; 1994; 88(2):223-5. PubMed ID: 8036682
[TBL] [Abstract][Full Text] [Related]
22. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
23. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
[TBL] [Abstract][Full Text] [Related]
24. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
El-On J; Bazarsky E; Sneir R
Exp Parasitol; 2007 Jun; 116(2):156-62. PubMed ID: 17306255
[TBL] [Abstract][Full Text] [Related]
25. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment.
el-On J; Sulitzeanu A; Schnur LF
Ann Trop Med Parasitol; 1991 Jun; 85(3):323-8. PubMed ID: 1746981
[TBL] [Abstract][Full Text] [Related]
26. Topical 15% Paromomycin-Aquaphilic for Bolivian Leishmania braziliensis Cutaneous Leishmaniasis: A Randomized, Placebo-controlled Trial.
Soto J; Soto P; Ajata A; Luque C; Tintaya C; Paz D; Rivero D; Berman J
Clin Infect Dis; 2019 Feb; 68(5):844-849. PubMed ID: 30260376
[TBL] [Abstract][Full Text] [Related]
27. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
[TBL] [Abstract][Full Text] [Related]
28. Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran.
Asilian A; Jalayer T; Nilforooshzadeh M; Ghassemi RL; Peto R; Wayling S; Olliaro P; Modabber F
Bull World Health Organ; 2003; 81(5):353-9. PubMed ID: 12856053
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment.
Ben Salah A; Zakraoui H; Zaatour A; Ftaiti A; Zaafouri B; Garraoui A; Olliaro PL; Dellagi K; Ben Ismail R
Am J Trop Med Hyg; 1995 Aug; 53(2):162-6. PubMed ID: 7677218
[TBL] [Abstract][Full Text] [Related]
30. Treatment of 'Old World' cutaneous leishmaniasis with aminosidine ointment: results of an open study in London.
Bryceson AD; Murphy A; Moody AH
Trans R Soc Trop Med Hyg; 1994; 88(2):226-8. PubMed ID: 8036683
[TBL] [Abstract][Full Text] [Related]
31. Studies on the topical treatment of experimental cutaneous leishmaniasis: the therapeutic effect of methyl benzethonium chloride and the aminoglycosides, gentamicin and paromomycin.
Carter KC; Alexander J; Baillie AJ
Ann Trop Med Parasitol; 1989 Jun; 83(3):233-9. PubMed ID: 2604461
[TBL] [Abstract][Full Text] [Related]
32. Successful Treatment of Cutaneous Leishmaniasis with Topical Paramomycin in a Child After Treatment Failure with Systemic Fluconazole.
Chacko A; Joseph M; Feltis T; Morris SK
Am J Trop Med Hyg; 2016 Oct; 95(4):793-794. PubMed ID: 27549634
[TBL] [Abstract][Full Text] [Related]
33. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.
Sosa N; Capitán Z; Nieto J; Nieto M; Calzada J; Paz H; Spadafora C; Kreishman-Deitrick M; Kopydlowski K; Ullman D; McCarthy WF; Ransom J; Berman J; Scott C; Grogl M
Am J Trop Med Hyg; 2013 Sep; 89(3):557-563. PubMed ID: 23857024
[TBL] [Abstract][Full Text] [Related]
34. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
Flaig MJ; Rupec J; Ruzicka T; Rupec RA
Hautarzt; 2007 Aug; 58(8):689-90, 692. PubMed ID: 17676349
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania (Leishmania) major and Leishmania (Leishmania) amazonensis.
Mussi SV; Fernandes AP; Ferreira LA
Parasitol Res; 2007 May; 100(6):1221-6. PubMed ID: 17206508
[TBL] [Abstract][Full Text] [Related]
36. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study.
Ben Salah A; Buffet PA; Morizot G; Ben Massoud N; Zâatour A; Ben Alaya N; Haj Hamida NB; El Ahmadi Z; Downs MT; Smith PL; Dellagi K; Grögl M
PLoS Negl Trop Dis; 2009; 3(5):e432. PubMed ID: 19415122
[TBL] [Abstract][Full Text] [Related]
37. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
38. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
El-On J; Jacobs GP; Witztum E; Greenblatt CL
Antimicrob Agents Chemother; 1984 Nov; 26(5):745-51. PubMed ID: 6517557
[TBL] [Abstract][Full Text] [Related]
39. Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice.
Bavarsad N; Fazly Bazzaz BS; Khamesipour A; Jaafari MR
Acta Trop; 2012 Oct; 124(1):33-41. PubMed ID: 22750480
[TBL] [Abstract][Full Text] [Related]
40. Treatment of cutaneous leishmaniasis by photodynamic therapy.
Gardlo K; Horska Z; Enk CD; Rauch L; Megahed M; Ruzicka T; Fritsch C
J Am Acad Dermatol; 2003 Jun; 48(6):893-6. PubMed ID: 12789181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
